Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)
Close on Nov 18, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Inhibikase Therapeutics's operating margin for the twelve months ending Sep 30, 2024 was -2006393700.0%. For fiscal 2023 it was -7712.0%, against -14686.2% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -7712.0% | +6974.2 |
| FY2022 | Dec 31, 2022 | -14686.2% | −14209.9 |
| FY2021 | Dec 31, 2021 | -476.2% | −72.7 |
| FY2020 | Dec 31, 2020 | -403.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -440356600.0% | −440349780.4 |
| Q3 FY2023 | Sep 30, 2023 | -5993.4% | +55906.2 |
| Q2 FY2023 | Jun 30, 2023 | -5328.1% | +65489.1 |
| Q1 FY2023 | Mar 31, 2023 | -7307.6% | +2773.8 |
| Q4 FY2022 | Dec 31, 2022 | -6819.6% | −6626.8 |
| Q3 FY2022 | Sep 30, 2022 | -61899.6% | −61713.0 |
| Q2 FY2022 | Jun 30, 2022 | -70817.1% | −70112.5 |
| Q1 FY2022 | Mar 31, 2022 | -10081.5% | −8320.0 |
| Q2 FY2021 | Jun 30, 2021 | -192.8% | −4.3 |
| Q1 FY2021 | Mar 31, 2021 | -186.6% | +12.9 |
| Q4 FY2020 | Dec 31, 2020 | -704.7% | – |
| Q3 FY2020 | Sep 30, 2020 | -1761.4% | – |
| Q2 FY2020 | Jun 30, 2020 | -188.5% | – |
| Q1 FY2020 | Mar 31, 2020 | -199.4% | – |
See a number that looks wrong?